Top 30 Indonesian Medical Equipment Public Companies Q3 2025 Revenue & Performance

1) Overall companies performance (Q3 2025 snapshot)
PT Jayamas Medica Industri Tbk
PT UBC Medical Indonesia Tbk
PT Hetzer Medical Indonesia Tbk
PT Kalbe Farma Tbk
PT Enseval Putera Megatrading Tbk
PT Siam Medical Products
PT Kimia Farma Tbk
PT Indofarma Tbk
PT Soho Global Health Tbk
PT Darya-Varia Laboratoria Tbk
PT Prodia Widyahusada Tbk
PT Medikaloka Hermina Tbk
PT Siloam International Hospitals Tbk
PT Mitra Keluarga Karyasehat Tbk
PT Tempo Scan Pacific Tbk
PT Pyridam Farma Tbk
PT Ikapharmindo Putramas Tbk
PT Penta Valent Tbk
PT Bkrigit Biofarmaka Teknologi Tbk
PT Metro Healthcare Indonesia Tbk
PT Sarana Meditama Metropolitan Tbk
PT Metro Healthcare Indonesia Tbk
PT Royal Prima Tbk
PT Enseval Putera Megatrading Tbk
PT UBC Medical Indonesia Tbk
PT Millennium Pharmacon International Tbk
PT Medela Potentia Tbk
PT Sejahteraraya Anugrahjaya Tbk
PT Murni Sadar Tbk
PT Charlie Hospital Semarang Tbk
2) Revenue results of major public companies in Indonesia summarized (per company)
PT Jayamas Medica Industri Tbk (OMED) - Revenue (9M25): ~IDR 1.47 trillion (~USD 88.1 million) Net profit Q3 2025 ~IDR 254.2 billion (~USD 15.2 million). The company grew revenue ~7.7% YoY amid strong demand in wound care, lab & biotech segments and expanded exports, particularly to the U.S. Gross margin improved ~11.5% YoY with healthy EBITDA margins (~22.7%).
PT Kalbe Farma Tbk - Net profit (9M25): ~IDR 2.63 trillion (~USD 157.6 million). Kalbe continued robust performance driven by diversified healthcare products including its medical device assembly subsidiary venture. Management cited steady domestic demand and mix benefits.
PT Tempo Scan Pacific Tbk - Net profit (9M25): ~IDR 1.14 trillion (~USD 68.3 million). Profitability supported by stable OTC and prescription demand alongside healthcare adjacencies.
PT Mitra Keluarga Karyasehat Tbk - PATMI (9M25): ~IDR 1.0 trillion (~USD 59.9 million). Revenues were supported by an improving private patient mix and corporate health programs.
PT Siloam International Hospitals Tbk - Net profit (9M25): ~IDR 761.3 billion (~USD 45.6 million). Improved occupancy and elective procedures drove better volumes, benefiting equipment utilisation.
PT Enseval Putera Megatrading Tbk - Net profit (9M25): ~IDR 603.4 billion (~USD 36.2 million). Distributor of medical products and equipment saw steady revenue and distribution growth.
PT Industri Jamu & Farmasi Sido Muncul Tbk - Net profit (9M25): ~IDR 818.5 billion (~USD 49.0 million). Consumer healthcare strength supported allied medical supply categories.
PT UBC Medical Indonesia Tbk - Listed healthcare supply company with exposure to clinical and diagnostic supply chains, included among major healthcare players.
PT Hetzer Medical Indonesia Tbk - Medical equipment maker; financials not disclosed in available earnings summaries but recognized as IDX-listed equipment supplier.
PT Darya-Varia Laboratoria Tbk - Net profit (Q3 2025): ~IDR 164.3 billion (~USD 9.8 million). Profit reflected stable core sales with modest growth.
3) Key trends & insights from Q3 2025
1) Resilience Amid Macro Pressures - Medical equipment companies and healthcare suppliers reported steady top-line growth despite cost pressures in hospitals and higher operational expenses. Diversified revenue streams helped many companies sustain margins.
2) Domestic Production Growth & Policy Support - Local manufacturing policies (TKDN) have boosted domestic device production share, reducing reliance on imports for many consumables and basic equipment categories.
3) Export & Supply Chain Shifts - Companies like OMED benefitted from global supply chain diversification (China +1) with stronger export growth to markets such as the U.S.
4) Hospital Recovery & Equipment Demand - As elective procedures and private pay volumes recovered, demand for hospital equipment and supplies rose, benefiting networks like Siloam and Mitra Keluarga.
5) Investor Sentiment - While the broader Medical Equipment subsector trend on IDX shows modest performance relative to other healthcare themes, investor focus remains on companies with sustainable margins and export potential.
4) Outlook for Q4 2025 and beyond
1) Growing Domestic Market - Structural demand for medical devices and supplies in Indonesia will likely expand with population growth, rising health awareness, and aging demographics.
2) Policy-Driven Localisation - Further support for local manufacturers is expected via government procurement preferences and export-oriented industrial initiatives.
3) Technology & Innovation- Investment in higher-value devices and digital health integration could raise sector margins, although capital intensity remains a barrier.
4) Export Potential - Companies with strong quality credentials have the chance to expand into APAC and Western markets through competitive pricing and diversified offerings a key strategic frontier for players like OMED.
5) Conclusion
Q3 2025 was a mixed but resilient quarter for Indonesian public companies with medical equipment exposure. While macroeconomic challenges and operational cost pressures persisted, solid performances from diversified healthcare conglomerates and specialized equipment suppliers underpinned industry stability. Notable trends include policy-driven localisation, shifting supply chains, and persistent underlying demand in both domestic and export markets. As the sector progresses into Q4 2025 and beyond, companies that embrace innovation, expand distribution, and improve operational efficiency are best positioned for sustainable growth.
Contact Information:
Tel: +1 626 2952 442 (US) ; +86-1082945717 (China)
+62 896 3769 3166 (Whatsapp)
Email: willyanto@qyresearch.com; global@qyresearch.com
Website: www.qyresearch.com

Contact Information:
Tel: +1 626 2952 442 (US) ; +86-1082945717 (China)
+62 896 3769 3166 (Whatsapp)
Email: willyanto@qyresearch.com; global@qyresearch.com
Website: www.qyresearch.com

About QY Research
QY Research has established close partnerships with over 71,000 global leading players. With more than 20,000 industry experts worldwide, we maintain a strong global network to efficiently gather insights and raw data.
Our 36-step verification system ensures the reliability and quality of our data. With over 2 million reports, we have become the world's largest market report vendor. Our global database spans more than 2,000 sources and covers data from most countries, including import and export details.
We have partners in over 160 countries, providing comprehensive coverage of both sales and research networks. A 90% client return rate and long-term cooperation with key partners demonstrate the high level of service and quality QY Research delivers.
More than 30 IPOs and over 5,000 global media outlets and major corporations have used our data, solidifying QY Research as a global leader in data supply. We are committed to delivering services that exceed both client and societal expectations.

This release was published on openPR.